{"name":"German CLL Study Group","slug":"german-cll-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Alemtuzumab i.v.","genericName":"Alemtuzumab i.v.","slug":"alemtuzumab-i-v","indication":"Chronic lymphocytic leukemia","status":"phase_1"},{"name":"Alemtuzumab s.c.","genericName":"Alemtuzumab s.c.","slug":"alemtuzumab-s-c","indication":"Chronic lymphocytic leukemia","status":"phase_1"},{"name":"CAL-101","genericName":"CAL-101","slug":"cal-101","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_2"},{"name":"Fludarabine mono","genericName":"Fludarabine mono","slug":"fludarabine-mono","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"Fludarabine plus Cyclophosphamide","genericName":"Fludarabine plus Cyclophosphamide","slug":"fludarabine-plus-cyclophosphamide","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"Fludarabine plus Darbopoetin","genericName":"Fludarabine plus Darbopoetin","slug":"fludarabine-plus-darbopoetin","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"FCCam","genericName":"FCCam","slug":"fccam","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Alemtuzumab i.v.","genericName":"Alemtuzumab i.v.","slug":"alemtuzumab-i-v","phase":"phase_1","mechanism":"CD52 is a surface protein on mature lymphocytes; Alemtuzumab binds to CD52 and induces cell death.","indications":["Chronic lymphocytic leukemia"],"catalyst":""},{"name":"Alemtuzumab s.c.","genericName":"Alemtuzumab s.c.","slug":"alemtuzumab-s-c","phase":"phase_1","mechanism":"CD52-targeting monoclonal antibody","indications":["Chronic lymphocytic leukemia"],"catalyst":""},{"name":"CAL-101","genericName":"CAL-101","slug":"cal-101","phase":"phase_2","mechanism":"CAL-101 is a selective, irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K).","indications":["Chronic lymphocytic leukemia (CLL)"],"catalyst":""},{"name":"FCCam","genericName":"FCCam","slug":"fccam","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fludarabine mono","genericName":"Fludarabine mono","slug":"fludarabine-mono","phase":"phase_3","mechanism":"Fludarabine is a purine analog that inhibits DNA synthesis by blocking ribonucleotide reductase and incorporating into DNA, leading to cell death in rapidly dividing lymphocytes.","indications":["Chronic lymphocytic leukemia (CLL)","Follicular lymphoma","Small lymphocytic lymphoma (SLL)"],"catalyst":""},{"name":"Fludarabine plus Cyclophosphamide","genericName":"Fludarabine plus Cyclophosphamide","slug":"fludarabine-plus-cyclophosphamide","phase":"phase_3","mechanism":"Fludarabine and cyclophosphamide work together as a chemotherapy combination that damages cancer cell DNA and suppresses immune function to treat chronic lymphocytic leukemia.","indications":["Chronic lymphocytic leukemia (CLL)","B-cell non-Hodgkin lymphoma"],"catalyst":""},{"name":"Fludarabine plus Darbopoetin","genericName":"Fludarabine plus Darbopoetin","slug":"fludarabine-plus-darbopoetin","phase":"phase_3","mechanism":"Fludarabine inhibits DNA synthesis in leukemic cells while darbopoetin stimulates red blood cell production to counteract chemotherapy-induced anemia.","indications":["Chronic lymphocytic leukemia (CLL)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOX0pDeVNmRTRIN1RHQlMxTmNLVlFwWGhuZnhyd19JeVlGcDU1V3MzOUdEdkNhTkJKOUt1czRVN2ZidkhXMTVHck43SkpFNTVMVG56N0NVQnJnMkRMRkJvekNoVEEwUTZybi1PSmxnTHU5N2VHY25uVWRoeWplbkpPbV9EbFNOR1dnZ25YbUNiMHBEOFYyWVhNWWVqNU9DSzBWU0Q1THNWczlzR1hHVXRuOG1VdXdMcG9qcVB3Ry12Q2s?oc=5","date":"2026-02-20","type":"regulatory","source":"Fierce Pharma","summary":"AstraZeneca's fixed-duration Calquence combo wins FDA nod as BeOne CLL rivalry heats up - Fierce Pharma","headline":"AstraZeneca's fixed-duration Calquence combo wins FDA nod as BeOne CLL rivalry heats up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQY25UUTc2aG5GS2k4VzFXTmtsWjU5V01zM0hvd2xidTIycjdtYzdsbXA3UTY2U191TV91SXZHR2JSMnJ3c0hzVmphcmQtS0pGUURtUEdLUXJYOUc2TWlneGpBMC1uOTNqaXdCbE04RHEtaDNVUk8xSVdJRkk1TzdGbUR5MlpFa0MzUW1nQVlIQzBic0dEYnpQZFM1SGxaMVcwMTJZODE4amJ3b1BQOHpPT0FjN1M?oc=5","date":"2025-09-08","type":"pipeline","source":"Fierce Pharma","summary":"With 'compelling' effect size, Eli Lilly's Jaypirca advances a step closer to first-line use in CLL - Fierce Pharma","headline":"With 'compelling' effect size, Eli Lilly's Jaypirca advances a step closer to first-line use in CLL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQYUNKQ1E4NUUzNDlCbUdNRDdDbjFlNmw1RWNSRGNUaUJwQzJ3bGlaU3FUQ1ZtS2VVejRSZXZLQWh0amdLam5sX0xrTFFkeXB0cFUzV2lsR0hNZGlMbzdsYURpbnVac2VCWTYxNllVNGVLN2tPdDRwUWtnWHItc2dENnJyNXQ0dDUtaGVUTGNra3BJelpwX2s1LTcwUFM1Y1ZUS3o2MmlMam9jd3Q4clc0d3Z0N29hb2M?oc=5","date":"2025-08-07","type":"pipeline","source":"jhoponline.com","summary":"Overview of the Current Development Landscape in Chronic Lymphocytic Leukemia, Part 3 - jhoponline.com","headline":"Overview of the Current Development Landscape in Chronic Lymphocytic Leukemia, Part 3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFByalFEXzZxOW12Y0hlM09nN0M3Ym9RRnVfYTRPVFJ1LTZMZnA3M3ItcU5LLUppU2ZsZmE0RjF2M1BxdFVPNFQ0YTRhR3NoTElVc2NaY0hSQ1NSM3FWUFZR?oc=5","date":"2025-02-20","type":"pipeline","source":"nature.com","summary":"Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL - nature.com","headline":"Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPYThZbzlSbGcxRDFhMjBxVXdhRjgxWVBNbzRWU0FaRDA1NFdNb3Q4NTlHcU1kOTN3R3N6SVZSbUM1cXN1ZUsxX3ZJOXZZZFlrQzRLUXRoRkdrUDd3ZmQ3LWEwUC1RcGZTU0tXRkNTVmd2NmxaNzVaVC02d2h5WDdTbVBuU00zcGdfc1cyY3NfMmR2LVhieDlLaEpvbjMyVUk?oc=5","date":"2024-04-17","type":"pipeline","source":"Pharmacy Times","summary":"Pirtobrutinib and BTK Inhibitors in the CLL Treatment Landscape - Pharmacy Times","headline":"Pirtobrutinib and BTK Inhibitors in the CLL Treatment Landscape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE9uOExDQ2JGVS1uRF9MWWhzY01sM2oxTFotY2JZZEo4RGV3VXNwZGJydlFEVlBQM3dUanlMNjNZV3d2Qk9WVlJub09jWUhQUllIenUyTlk2V0tqVVlWemRGQ0QzVG9KT3V2a3c?oc=5","date":"2024-04-05","type":"regulatory","source":"Wiley Online Library","summary":"American Journal of Hematology | Blood Research Journal - Wiley Online Library","headline":"American Journal of Hematology | Blood Research Journal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPM2NOaFItY1JpU25Ed1YtSlFuQVVBOGEzaFpKU2d0TjdHeHU1d24yM2RZY04xYmdlNGd0bVpBYkd4SnhzaGFBVmEwempTTzcwQWxrS2RxQWxvbkgzR3RiX0pvRXpWcmV1X3RodEtTeHRDTE92Uy1MSkR4UDZnekEwY3RIRzRkYjdLbHNTaFV3RXRWV0hMX25xQkstbVVCU2E3MmRGdG0zMmIyTEpoLVVINkFYN0N4NjR3VTBCTEhXWW9LVWxPdUpWeVp6VU5kb0pLNGNIcXJ4WlZLaE96RHc?oc=5","date":"2023-06-09","type":"pipeline","source":"Pharmacy Times","summary":"Venetoclax Combinations Have Sustained Long-term Benefits for Relapsed, Refractory Chronic Lymphocytic Leukemia - Pharmacy Times","headline":"Venetoclax Combinations Have Sustained Long-term Benefits for Relapsed, Refractory Chronic Lymphocytic Leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNN0VUckdrZHdER1E2ZHlaWlJ4VFlQTW0tVGt2WW1IeEh3bkJRQTk4TlNKSkF5NThHOENNWTJfdkxTN0g0ZWcyNGxuYkcxRTdTOG1MamVyY2F4S3p4X2oxWXBjYXNkcWttbW9zNmZrd3dLcmZsVXdUUEhuaks3bE5qSmt2RUprVFE3MXJOUnNFSFlHTkJKZ2p3ZWt1UnV4VERabGtMeFk0VjB5X015TEFaMVNpSQ?oc=5","date":"2022-12-15","type":"pipeline","source":"Lymphoma Hub","summary":"Educational theme | Targeted treatment for elderly patients with CLL - Lymphoma Hub","headline":"Educational theme | Targeted treatment for elderly patients with CLL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOVFlTWE00ZDJ3dUNmWTVuOUlFQVJNZ3FqOHFETER4eE5FdnQwR0gySmlXVlI4Z1dqanE2QWNIdGI3Z3JxYmV4UzI2eVdUY0dNNzR3SVd0cllMOEZHMjdvV2FWOFJJcnpRd3ZtX2pOSWdMOHlPNVRZQ3hvRFlyZ2xHZVk4c0d4NHk0cmRaaFJqZGhkY0htSlVYeUFfU24xcUFOQ2x4WEo5R1NONjl0TkhlQVJ4emdQdUJQaXE0YWZNMkhydEU?oc=5","date":"2019-05-16","type":"regulatory","source":"Hematology Advisor","summary":"Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL - Hematology Advisor","headline":"Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNM0tVRTZYblZmUnlQRDZfSW5XZ0JHVW5HaW1mUlo1RndmVDh5LVNPYWdySjU1M042LVluRXd3dlczWWNEQzlfMkJ1eWV2LXUzV01GdXRrSEhGaFR1VmRrUm9NZ0p1NXVHeGJDN3VzdHVUYnhsU3dMV1poY3FIcFRBREtLMmxZaGdHOEI1TVZuNEF5dw?oc=5","date":"2019-05-15","type":"regulatory","source":"OncLive","summary":"FDA Approves Venetoclax/Obinutuzumab Combo for Frontline CLL - OncLive","headline":"FDA Approves Venetoclax/Obinutuzumab Combo for Frontline CLL","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5LY2dqRjhzLWZFak16MElyN0R5aHVoQ0RIaTk5REdYWEdRcnVjUUxQSkNaeTJIcTFHR2ZJYVlyaEFnekFndmNsTXJaSnZBZXVFcGVIODcxZGg3dWU1SFQ4Nw?oc=5","date":"2018-04-23","type":"pipeline","source":"NEJM","summary":"Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia - NEJM","headline":"Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5HbVh4dnJIVkV6VzlMbXlOYkp4RjVuWjlSSkpwbENpUTNPbzNqUDhXbmFGZE8zblFwZktIc1JneHlfSGtiVzBFUE5yYTJYbElwQ2dCRw?oc=5","date":"2017-08-14","type":"trial","source":"nature.com","summary":"Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group - nature.com","headline":"Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CL","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_1":2,"phase_2":2,"phase_3":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}